|
V.V. Gudkova (1), E.I. Kimelfeld (1), L.V. Stakhovskaya (1, 2)
CENTRAL NEUROPATHIC PAIN AS ONE OF THE SIGNIFICANT PROBLEMS OF THE POST-STROKE PERIOD
|
8-12 |
|
V.V. Zakharov
PREVENTION AND TREATMENT OF LATE COMPLICATIONS OF PARKINSON’S DISEASE
|
14-19 |
|
A.M. Tkachev (1), E.S. Akarachkova (2), A.V. Smirnova (3), A.V. Ilyushin (1), N.V. Kulyutkin (4), Yu.V. Smerya (5)
SPONTANEOUS REGRESSION OF LUMBAR DISC HERNIATIONS AGAINST THE BACKGROUND OF THERAPY WITH GABAPENTIN
|
20-24 |
|
P.I. Novikov, E.A. Makarov, A.S. Zykova, S.V. Moiseyev
CASE OF SAPHO-SYNDROME – DIAGNOSING PATH AND EXPERIENCE OF SUCCESSIVE USE OF PAMIDRONATE
|
25-30 |
|
A.N. Bogolepova (1), E.V. Makhnovich (1), A.N. Zhuravleva (2), Т.А. Donskikh (3)
VISUAL DISTURBANCES AND ALZHEIMER’S DISEASE
|
31-36 |
|
N.V. Chichasova
MODERN APPROACHES TO TREATMENT OF OSTEOARTHRITIS: THE ROLE OF INJECTABLE SLOW-ACTING SYMPTOM-MODIFIING PREPARATIONS
|
37-43 |
|
I.A. Zolotovskaya, I.L. Davydkin
ANTIRESORPTIVE-CYTOCIN EFFICIENCY OF CHONDROPROTECTIVE THERAPY OF OSTEOARTHRITIS AND NON-SPECIFIC LOW BACK PAIN (RESULTS OF ALBATROS STUDY)
|
44-52 |
|
S.S. Dotsenko, L.N. Shilova
CLINICAL AND LABORATORY PREDICTORS OF EFFECTIVENESS OF BACKGROUND THERAPY IN RHEUMATOID ARTHRITIS
|
53-56 |
|
M.Yu. Maksimova, A.S. Moskvicheva
THROMBO ASS® IN THE SECONDARY PREVENTION OF HYPERTENIC SMALL DEEP (LUCUNAR) CEREBRAL INFARCTIONS
|
57-61 |
|
E.A. Kovrazhkina
NEUROPHYSIOLOGICAL PARAMETERS OF SEGMENTAL AND SUPRASEGMENTAL CONDUCTION IN PATIENTS WITH VARIOUS TIMING OF SPINAL CORD INJURY
|
62-65 |
|
T.V. Danilova (1, 2), Z.K. Latypova (1, 2), D.R. Khasanova (1, 2)
CLINICAL-ELECTROENCEPHALOGRAPHIC FEATURES IN PATIENTS WITH EPILEPSY DEVELOPED AGAINST THE BACKGROUND OF CEREBRAL ISCHEMIA
|
66-71 |
|
A.A. Kondur
PREDICTORS OF EFFICIENCY OF NEUROREHABILITATION IN PATIENTS WITH MOTOR DISORDERS USING THE BRAIN-COMPUTER NEUROINTERFACE
|
72-77 |
|
E.A. Kulyaev (1), A.V. Grafov (1), O. V. Falameeva (1), V.S. Kholodkin (1), M.A Sadovoy (1, 2), O.V. Tsygankova (2)
EXPERIENCE OF THE USE OF ZOLEDRONIC ACID (REZOLLASTIN 5 MG/6.25 ML, OOO «NATIVA») IN PATIENTS WITH LOW BONE MINERAL DENSITY IN THE SETTINGS OF THE CENTER FOR PREVENTION OF OSTEOPOROSIS OF NOVOSIBIRSK SRITO
|
78-81 |
|
E.V. Silina (1), I.A. Zimin (2)
RUSSIAN MARKET OF NEUROPROTECTORS (PUBLICATION AND RESEARCH ACTIVITY, RATING, MARKET VOLUME, SALES)
|
82-91 |
|
M.A. Savina (1), E.A. Petrova (2), Т.P. Safarova (1)
PREVENTION OF POST-STROKE DEPRESSION
|
92-95 |
Русский
